Casi Pharmaceuticals Inc Expected To Post A Loss Of 61 Cents A Share: Earnings Preview

CASI Pharmaceuticals

09/05/2025 15:28

CASI Pharmaceuticals Inc CASI.OQ CASI.O is expected to show a rise in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

The Beijing-based  company is expected to report a 78.9% increase in revenue to $6.1 million from $3.41 million a year ago, according to the estimate from one analyst, based on LSEG data.

​LSEG's mean analyst estimate for CASI Pharmaceuticals Inc is for a loss of 61 cents per share.

The one available analyst rating on the shares is "buy".

The average consensus recommendation for the pharmaceuticals peer group is also "Buy".​

Wall Street's median 12-month price target for CASI Pharmaceuticals Inc is $4.00​, above​ its last closing price of $1.94. ​​​

This summary was machine generated May 9 at 14:28 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)